Members
One of the Stop TB Partnership's seven Working Groups, the Working Group on New Drugs (WGND) is a network of expert individuals committed to accelerating the development of effective and affordable new therapies for TB. The WGND acts as a forum to facilitate global collaborations for the development of new TB drugs and promotes coordination of all stakeholders in this process. WGND members are individuals rather than organizations and include those working in basic research and TB drug R&D as well as regulators, funders, implementers, advocates, policy-makers and affected community representatives. WGND members pursue and fund their own activities and, through the WGND, collaborate on joint initiatives.
If you are interested in joining the WGND, please download and complete the Membership Application Form below. Return your completed form to the WGND Secretariat, via email to StopTBDrugWG@tballiance.org, or by post to Working Group on New Drugs Secretariat C/O TB Alliance, 40 Wall St, 24th Floor, New York, NY 10005, USA. You will be notified by email when your Application has been received and when a decision has been made.
Download Membership Application Form
Members List (97 total members, updated Dec 2, 2008)
Dr. Koen Andries, Tibotec
Dr. Venkataraman, Balasubramanian AstraZeneca R&D India
Dr Tanjore Balganesh, AstraZeneca R&D India
Dr Maria Beconi, TB Alliance
Dr. William Bishai, Johns Hopkins School of Medicine
Prof. Jonathan Blackburn, "University of Cape Town"
Dr. Amy Bloom, United States Agency for International Development
Ms. Florence Bordon-Pallier, Sanofi-Aventis
Dr. Allen Casey, Infectious Disease Research Institute
Prof. Gail Cassell, Eli Lilly and Company
Dr. Kenneth Castro, U.S. Centers for Disease Control and Prevention
Dr. Richard Chaisson, Johns Hopkins University Center for TB Research
Dr Isabelle Cieren-Puiseux, sanofi-aventis
Dr. Stewart Cole, Ecole Polytechnique Fédérale de Lausanne (EPFL)
Dr. Michael Cynamon, VAMC, SUNY, Upstate Medical University
Dr Karel de Beule, Tibotec
Dr Mary Ann de Groote, Colorado State University
Dr. Noroi Doi, Japan Anti-Tuberculosis Association; Research Institute of Tuberculosis
Dr. Carol Dukes Hamilton, Infectious Diseases Society of America; Duke University Medical Center
Dr. Ken Duncan, Bill & Melinda Gates Foundation
Dr. Leo Einck, Sequella, Inc.
Dr. Marcos Espinal, Stop TB Partnership Secretariat
Dr. Bernard Fourie, Medicine in Need (Mend)
Dr. Scott Franzblau, Institute for Tuberculosis Research, University of Illinois at Chicago
Dr. Maria Freire, Lasker Foundation
Dr Jennifer Fujii, Vertex Pharmaceuticals
Dr. Barrington Furr, AstraZeneca
Dr Lawrence Geiter, Otsuka Pharmaceutical Company
Dr Jan Gheuens, Bill & Melinda Gates Foundation
Dr. Ann Ginsberg, TB Alliance
Dr. Federico Gómez de las Heras, GlaxoSmithKline
Dr. Jacques Grosset, Johns Hopkins University School of Medicine
Dr Trudy Grossman, Vertex Pharmaceuticals
Dr. Malgosia Grzemska, World Health Organization
Mr. Mark Harrington, Treatment Action Group
Dr Gary Horwith, Sequella, Inc.
Ms. Heather Ignatius, TB Alliance
Dr. Amina Jindani, St. George’s, University of London
Dr Rajender Kamboj, Lupin Limited
Dr Hiromu Kawakubo, Asahi Kasei Chemicals Corporation
Dr Edward Kesicki, Infectious Disease Research Institute
Dr. Barbara Laughon, National Institute of Allergy and Infectious Diseases, NIH, DHHS
Dr Martino Laurenzi, TB Alliance
Dr. Didier Leboulleux, Sanofi aventis
Dr. Anne Lenaerts, Colorado State University
Dr. Christian Lienhardt, International Union Against Tuberculosis and Lung Diseases (The Union)
Dr Christopher Locher, Vertex Pharmaceuticals
Mr. James Love, Knowledge Ecology International (KEI)
Dr. Zhenkun Ma, TB Alliance
Dr Mamodikoe Makhene, NIH
Dr Bonita Mangura, New Jersey Medical School Global TB Institute at UMDNJ
Prof. Stephen Matlin, Global Forum for Health Research
Dr. David McNeeley, Tibotec
Prof. Dennis Mitchison, St Georges. University of London
Dr. Carole Mitnick, Harvard Medical School
Dr Peter Mueller, Vertex Pharmaceuticals
Dr Ute Muh, Vertex Pharmaceuticals
Dr. Carol Nacy, Sequella, Inc.
Dr. P. R. Narayanan, Tuberculosis Research Centre, Chennai (retired)
Dr. Rick O’Brien, Foundation for Innovative New Diagnostics
Mr. Matti Ojanen, AstraZeneca PLC
Dr. Philip Onyebujoh, WHO/Special Programme for Research and Training in Tropical Diseases (TDR)
Dr. Ian Orme, Colorado State University
Mr. Nelson Otwoma, Positive Familes Network (+FN)
Dr. Shreemanta Parida, Max Planck institute for Infection Biology
Dr Tanya Parish, Infectious Disease Research Institute
Dr Jerome Premmereur, TB Alliance
Dr. Marina Protopopova, Sequella, Inc.
Dr. Mario Raviglione, World Health Organization
Dr. John Rex, AstraZeneca R&D
Prof. Robert Ridley, WHO/Special Programme for Research and Training in Tropical Diseases (TDR)
Dr. Doris Rouse, RTI International
Dr Boitumelo Semete, Council of Scientific Industrial Research (CSIR) in South Africa
Dr. Tado Shimao, JATA Research Institute of Tuberculosis (RIT)
Dr Gerald Siuta, TB Alliance
Dr. Christine Sizemore, National Institute of Allergy & Infectious Diseases (NIH)
Prof. Peter Small, Bill & Melinda Gates Foundation
Dr. Melvin Spigelman, TB Alliance
Dr. Martin Springsklee, Bayer Healthcare
Dr. Charles K. Stover, Pfizer Inc
Dr Hulda Swai, Council of Scientific Industrial Research (CSIR) in South Africa
Mr. Javid Syed, Treatment Action Group
Dr John Thomson, Vertex Pharmaceuticals
Dr. Tamari Trapaidze, Welfare Foundation
Dr. Cynthia Tuthill, SciClone Pharmaceuticals, Inc
Dr. Anna Upton, TB Alliance
Dr Christo van Niekerk, TB Alliance
Mr. Wim Vandevelde, European AIDS Treatment Group (EATG)
Dr. Andrew Vernon, U.S. Centers for Disease Control and Prevention
Mr. Todd Waldman, Easton Associates
Prof. Gerhard Walzl, Stellenbosch University
Dr Tiansheng Wang, Vertex Pharmaceuticals
Dr M. Gerard Waters, TB Alliance
Dr Charles Wells, Otsuka Pharmaceutical Company
Dr. William Wells, TB Alliance
Ms. Claire Wingfield, Treatment Action Group
Dr. Abubakar Yaro, Africa Health Research Organization
|
